Can Gut Hormones Control Appetite and Prevent Obesity?

被引:39
作者
Chaudhri, Owais B. [1 ]
Wynne, Katie [1 ]
Bloom, Stephen R. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Dept Metab Med, London W12 0NN, England
关键词
D O I
10.2337/dc08-s269
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The current obesity epidemic is fuelled by the availability of highly palatable, calorie-dense food, and the low requirement for physical activity in our modem environment. If energy intake exceeds energy use, the excess calories are stored as body fat. Although the body has mechanisms that act to maintain body weight over time, they primarily defend against. starvation and are less robust in preventing the development of obesity. Knowledge of this homeostatic System that controls body weight has increased exponentially over the last decade and has revealed new possibilities for the treatment of obesity and its associated comorbidities. One therapeutic target is the development of agents based on the gastrointestinal hormones that control appetite. This review discusses the hormones oxyntomodulin, peptide YY, glucagon-like peptide 1, pancreatic polypeptide, and ghrelin and their emerging potential as anti-obesity treatments.
引用
收藏
页码:S284 / S289
页数:6
相关论文
共 83 条
[1]   The inhibitory effects of peripheral administration of peptide YY3-36 and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal-brainstem-hypothalamic pathway [J].
Abbott, CR ;
Monteiro, M ;
Small, CJ ;
Sajedi, A ;
Smith, KL ;
Parkinson, JRC ;
Ghatei, MA ;
Bloom, SR .
BRAIN RESEARCH, 2005, 1044 (01) :127-131
[2]   Obesity in North America - An overview [J].
Allison, DB ;
Saunders, SE .
MEDICAL CLINICS OF NORTH AMERICA, 2000, 84 (02) :305-+
[3]   Mouse pancreatic polypeptide modulates food intake, while not influencing anxiety in mice [J].
Asakawa, A ;
Inui, A ;
Ueno, N ;
Fujimiya, M ;
Fujino, MA ;
Kasuga, M .
PEPTIDES, 1999, 20 (12) :1445-1448
[4]   Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure [J].
Baggio, LL ;
Huang, QL ;
Brown, TJ ;
Drucker, DJ .
GASTROENTEROLOGY, 2004, 127 (02) :546-558
[5]   Gut hormone PYY3-36 physiologically inhibits food intake [J].
Batterham, RL ;
Cowley, MA ;
Small, CJ ;
Herzog, H ;
Cohen, MA ;
Dakin, CL ;
Wren, AM ;
Brynes, AE ;
Low, MJ ;
Ghatei, MA ;
Cone, RD ;
Bloom, SR .
NATURE, 2002, 418 (6898) :650-654
[6]   Inhibition of food intake in obese subjects by peptide YY3-36 [J].
Batterham, RL ;
Cohen, MA ;
Ellis, SM ;
Le Roux, CW ;
Withers, DJ ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (10) :941-948
[7]   Pancreatic polypeptide reduces appetite and food intake in humans [J].
Batterham, RL ;
Le Roux, CW ;
Cohen, MA ;
Park, AJ ;
Ellis, SM ;
Patterson, M ;
Frost, GS ;
Ghatei, MA ;
Bloom, SR .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (08) :3989-3992
[8]   Feeding response to ghrelin agonist and antagonist in lean and obese Zucker rats [J].
Beck, B ;
Richy, S ;
Stricker-Krongrad, A .
LIFE SCIENCES, 2004, 76 (04) :473-478
[9]   Interim analysis of the effects of exenatide treatment on A1C, weight and cardiovascular risk factors over 82 weeks in 314 overweight patients with type 2 diabetes [J].
Blonde, L. ;
Klein, E. J. ;
Han, J. ;
Zhang, B. ;
Mac, S. M. ;
Poon, T. H. ;
Taylor, K. L. ;
Trautmann, M. E. ;
Kim, D. D. ;
Kendall, D. M. .
DIABETES OBESITY & METABOLISM, 2006, 8 (04) :436-447
[10]   PYY3-36 as an anti-obesity drug target [J].
Boggiano, MM ;
Chandler, PC ;
Oswald, KD ;
Rodgers, RJ ;
Blundell, JE ;
Ishii, Y ;
Beattie, AH ;
Holch, P ;
Allison, DB ;
Schindler, M ;
Arndt, K ;
Rudolf, K ;
Mark, M ;
Schoelch, C ;
Joost, HG ;
Klaus, S ;
Thöne-Reineke, C ;
Benoit, SC ;
Seeley, RJ ;
Beck-Sickinger, AG ;
Koglin, N ;
Raun, K ;
Madsen, K ;
Wulff, BS ;
Stidsen, CE ;
Birringer, M ;
Kreuzer, OJ ;
Deng, XY ;
Whitcomb, DC ;
Halem, H ;
Taylor, J ;
Dong, J ;
Datta, R ;
Culler, M ;
Ortmann, S ;
Castañeda, TR ;
Tschöp, M .
OBESITY REVIEWS, 2005, 6 (04) :307-322